Literature DB >> 3501324

Local immune responses after intravesical BCG treatment for carcinoma in situ.

M I el-Demiry1, G Smith, A W Ritchie, K James, J A Cumming, T B Hargreave, G D Chisholm.   

Abstract

The lymphoid cellular infiltrates in the bladder biopsies from patients with carcinoma in situ before and after BCG intravesical therapy have been determined and characterised. This has been achieved using a panel of monoclonal antibody probes in an indirect immunoperoxidase technique. These studies have revealed the predominance of T-cells of the helper/inducer phenotype (T4+), beta-lymphocytes (B1+) and macrophages (Leu M3+, 3.9+) in bladder biopsies after BCG therapy. HLA.DR antigens were also expressed on the lymphoid cells infiltrate as well as the urothelial cells. These results suggest that the components of an active immune response were present and enhanced in the bladder wall after BCG therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501324     DOI: 10.1111/j.1464-410x.1987.tb05039.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  15 in total

1.  A tribute to professor Geoffrey D Chisholm CBE ChM PPRCS Ed FRCS Eng FRCP Ed FRCPSG FRACS (Hon) FCSSA (Hon) FACS (Hon) FRSE.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1996       Impact factor: 5.344

Review 2.  Medical management of patients with refractory carcinoma in situ of the bladder.

Authors:  J C Kim; G D Steinberg
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?

Authors:  J S Teppema; E C de Boer; P A Steerenberg; A P van der Meijden
Journal:  Urol Res       Date:  1992

4.  Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG.

Authors:  E Pieras-Ayala; J Palou-Redorta; J I Tomero-Ruiz; M Montlleó-González; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 6.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

7.  Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

Authors:  E C de Boer; T M De Reijke; D H Schamhart; P C Vos; K H Kurth
Journal:  Urol Res       Date:  1993

8.  The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.

Authors:  A M Jackson; S Prescott; S J Hawkyard; K James; G Chisholm
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 9.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

10.  Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.

Authors:  A M Jackson; A B Alexandroff; M McIntyre; K Esuvaranathan; K James; G D Chisholm
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.